Drug developers face long odds and complex regulatory challenges when it comes to crafting a suitable candidate. In fact, only one of every 10 drug candidates gain regulatory approval, and when they do, it takes an average of 14 years and costs well over $2 billion.   So what makes for a successful candidate? It starts with a suitable screening platform that identifies targets and the molecules that bind to them to create a therapeutic response. Retrogenix is one such platform that the top 20 drug developers in the world currently use to increase their chances of success thanks to its unique technology that doesn’t require animal models or human tissue to evaluate effectiveness.   Join us to find out how Retrogenix works to identify targets, accelerate drug development, get vulnerable patients the therapies they need more quickly, and adapt to meet the growing demands of regulatory agencies. Show Notes 

Charles River Acquires Retrogenix 

Retrogenix Cell Microarray Technology 

De-risking Therapies and Vaccines for Use During Pregnancy 

Assessing ADC Anticancer Therapeutics via Antibody Specificity Screening 

Screening and Profiling Assays 

Off-Target Screening Cell Microarray Assay  

Webinar: Building a comprehensive lead enabling library  

Poster: Off-target Assessment of Biotherapeutics for us During Pregnancy 
Case Study: Antibody Drug Conjugate Off-Target Binding Screen